TrialLeukemia2023

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.

Andreas Hochhaus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.